KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Leases: 2022-2024

  • Regeneron Pharmaceuticals' Operating Leases rose 18.16% to $954.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $954.4 million, marking a year-over-year increase of 18.16%. This contributed to the annual value of $954.4 million for FY2024, which is 18.16% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Operating Leases of $954.4 million as of Q4 2024, which was up 18.16% from $807.7 million recorded in Q4 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Operating Leases peaked at $954.4 million during Q4 2024, and registered a low of $788.2 million during Q4 2022.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Operating Leases value was $807.7 million (recorded in 2023), while the average stood at $850.1 million.
  • Data for Regeneron Pharmaceuticals' Operating Leases shows a peak YoY rose of 18.16% (in 2024) over the last 5 years.
  • Regeneron Pharmaceuticals' Operating Leases (Quarterly) stood at $788.2 million in 2022, then increased by 2.47% to $807.7 million in 2023, then increased by 18.16% to $954.4 million in 2024.
  • Its last three reported values are $954.4 million in Q4 2024, $807.7 million for Q4 2023, and $788.2 million during Q4 2022.